CN1882345A - 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉 - Google Patents

作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉 Download PDF

Info

Publication number
CN1882345A
CN1882345A CNA200480030549XA CN200480030549A CN1882345A CN 1882345 A CN1882345 A CN 1882345A CN A200480030549X A CNA200480030549X A CN A200480030549XA CN 200480030549 A CN200480030549 A CN 200480030549A CN 1882345 A CN1882345 A CN 1882345A
Authority
CN
China
Prior art keywords
alkyl
phenyl
heteroaryl
base
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480030549XA
Other languages
English (en)
Chinese (zh)
Inventor
S·拉姆西
P·A·任豪
S·萨布拉马尼安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES and DIAGNOSTIC Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1882345A publication Critical patent/CN1882345A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200480030549XA 2003-10-16 2004-10-15 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉 Pending CN1882345A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51185103P 2003-10-16 2003-10-16
US60/511,851 2003-10-16

Publications (1)

Publication Number Publication Date
CN1882345A true CN1882345A (zh) 2006-12-20

Family

ID=34465285

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480030549XA Pending CN1882345A (zh) 2003-10-16 2004-10-15 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉

Country Status (10)

Country Link
US (3) US7691866B2 (enExample)
EP (1) EP1680122A1 (enExample)
JP (1) JP2007509059A (enExample)
KR (1) KR20070029110A (enExample)
CN (1) CN1882345A (enExample)
AU (1) AU2004281154A1 (enExample)
CA (1) CA2542329A1 (enExample)
IL (1) IL174470A0 (enExample)
MX (1) MXPA06003607A (enExample)
WO (1) WO2005037285A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298792A (zh) * 2010-11-19 2013-09-11 利亘制药公司 杂环胺及其用途
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN103896922B (zh) * 2012-12-25 2017-05-03 上海科胜药物研发有限公司 新的舒尼替尼盐及其制备方法
CN107245056A (zh) * 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
CN108794411A (zh) * 2011-09-14 2018-11-13 润新生物公司 某些化学实体、组合物及方法
CN111072500A (zh) * 2019-11-15 2020-04-28 山东罗欣药业集团恒欣药业有限公司 一种盐酸氨溴索的制备方法
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
CN1933839A (zh) * 2004-01-23 2007-03-21 安进公司 化合物和使用方法
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20060292537A1 (en) * 2005-06-27 2006-12-28 Arcturus Media, Inc. System and method for conducting multimedia karaoke sessions
KR20080074220A (ko) * 2005-12-08 2008-08-12 밀레니엄 파머슈티컬스 인코퍼레이티드 키나아제 억제 활성을 갖는 비시클릭 화합물
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
CA2658462C (en) 2006-07-20 2011-09-27 Amgen Inc. Substituted pyridone compounds and methods of use
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
TW200829566A (en) * 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
CA2678725A1 (en) * 2007-02-20 2008-08-28 The Mobile Star Corp. Self operated computerized karaoke recording booth
EP2195296A1 (en) 2007-09-27 2010-06-16 F. Hoffmann-Roche AG Quinoline derivatives as 5ht5a receptor antagonists
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009050228A2 (en) * 2007-10-18 2009-04-23 Novartis Ag Csf-1r inhibitors for treatment of cancer and bone diseases
US20100311965A1 (en) 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009111279A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
KR20100122505A (ko) * 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
KR101713501B1 (ko) 2008-03-17 2017-03-07 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
PE20120424A1 (es) 2008-12-29 2012-05-04 Fovea Pharmaceuticals Compuestos de quinazolina sustituidos
JP2012517971A (ja) 2009-02-13 2012-08-09 フォーヴィア・ファーマシューティカルズ キナーゼ阻害薬としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン類
EP2440048B8 (en) * 2009-06-09 2015-12-16 NantBioScience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
WO2010143169A2 (en) * 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
KR101630283B1 (ko) * 2009-06-25 2016-06-14 한화테크윈 주식회사 영상 보안 시스템에서 부호화 장치
KR101650981B1 (ko) 2009-09-03 2016-08-24 바이오에너제닉스 Ｐａｓｋ의 억제를 위한 복소환 화합물
US8553906B2 (en) * 2010-02-02 2013-10-08 Creative Technology Ltd Apparatus for enabling karaoke
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
JP5980812B2 (ja) * 2011-01-05 2016-08-31 バイオエナジェニックス Ｐａｓｋの阻害のための複素環化合物
WO2013043935A1 (en) 2011-09-21 2013-03-28 Neupharma, Inc. Certain chemical entites, compositions, and methods
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2916838B1 (en) 2012-11-12 2019-03-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US20220227740A1 (en) * 2019-04-15 2022-07-21 Tosk, Inc. Modulators of RAS GTPase
US12180220B2 (en) * 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
US20220112178A1 (en) * 2020-10-14 2022-04-14 Tosk, Inc. Small Molecule Modulators of RAS GTPase
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2739505A (en) * 1952-02-04 1956-03-27 Gillette Edwin Method and means for producing composite talking pictures
GB900779A (en) * 1959-04-22 1962-07-11 Monsanto Chemicals Quinazolines
US3177218A (en) * 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
US4149190A (en) * 1977-10-17 1979-04-10 Xerox Corporation Automatic gain control for video amplifier
US4408221A (en) * 1981-09-22 1983-10-04 Mccoy Reginald F H Television chroma-key systems
DK190983A (da) * 1982-05-01 1983-11-02 Wellcome Found 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
US5051817A (en) * 1988-11-18 1991-09-24 Rohm Co., Ltd. Superimposing system
JP3206619B2 (ja) * 1993-04-23 2001-09-10 ヤマハ株式会社 カラオケ装置
JP3542821B2 (ja) * 1994-03-31 2004-07-14 ヤマハ株式会社 映像合成システムに特徴を有するカラオケ装置
US5541666A (en) * 1994-07-06 1996-07-30 General Instrument Method and apparatus for overlaying digitally generated graphics over an analog video signal
JP3662969B2 (ja) * 1995-03-06 2005-06-22 富士通株式会社 カラオケシステム
KR100413611B1 (ko) * 1995-04-21 2004-05-20 소니 가부시끼 가이샤 영상신호의위상동기방법,회로및합성장치
US6400374B2 (en) * 1996-09-18 2002-06-04 Eyematic Interfaces, Inc. Video superposition system and method
JP2957977B2 (ja) * 1997-10-30 1999-10-06 三洋電機株式会社 ビデオカメラ
US6514083B1 (en) * 1998-01-07 2003-02-04 Electric Planet, Inc. Method and apparatus for providing interactive karaoke entertainment
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020072047A1 (en) * 1999-12-13 2002-06-13 Michelson Daniel R. System and method for generating composite video images for karaoke applications
AU784748B2 (en) * 1999-12-17 2006-06-08 Novartis Vaccines And Diagnostics, Inc. Bicyclic inhibitors of glycogen synthase kinase 3
US6978051B2 (en) * 2000-03-06 2005-12-20 Sony Corporation System and method for capturing adjacent images by utilizing a panorama mode
WO2001099413A2 (en) * 2000-06-20 2001-12-27 Koninklijke Philips Electronics N.V. Karaoke system
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
DE60218445T2 (de) 2001-04-20 2007-11-29 Bayer Pharmaceuticals Corp., West Haven Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
US7035915B1 (en) * 2001-09-05 2006-04-25 Cisco Technology, Inc. Method and apparatus for IP address assignment
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
CA2522522A1 (en) * 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds
US20070047834A1 (en) * 2005-08-31 2007-03-01 International Business Machines Corporation Method and apparatus for visual background subtraction with one or more preprocessing modules
US7570881B2 (en) * 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298792A (zh) * 2010-11-19 2013-09-11 利亘制药公司 杂环胺及其用途
CN107245056A (zh) * 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
CN108794411A (zh) * 2011-09-14 2018-11-13 润新生物公司 某些化学实体、组合物及方法
CN108794411B (zh) * 2011-09-14 2022-06-07 润新生物公司 某些化学实体、组合物及方法
CN103896922B (zh) * 2012-12-25 2017-05-03 上海科胜药物研发有限公司 新的舒尼替尼盐及其制备方法
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
CN111072500A (zh) * 2019-11-15 2020-04-28 山东罗欣药业集团恒欣药业有限公司 一种盐酸氨溴索的制备方法
CN111072500B (zh) * 2019-11-15 2022-12-06 山东罗欣药业集团恒欣药业有限公司 一种盐酸氨溴索的制备方法

Also Published As

Publication number Publication date
EP1680122A1 (en) 2006-07-19
AU2004281154A1 (en) 2005-04-28
JP2007509059A (ja) 2007-04-12
IL174470A0 (en) 2006-08-01
KR20070029110A (ko) 2007-03-13
MXPA06003607A (es) 2006-06-05
US7691866B2 (en) 2010-04-06
US20050084835A1 (en) 2005-04-21
US20090317359A1 (en) 2009-12-24
WO2005037285A1 (en) 2005-04-28
US20050085482A1 (en) 2005-04-21
CA2542329A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
CN1882345A (zh) 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
CN1655779A (zh) 取代的吲哚及其作为Raf激酶抑制剂的应用
CN1886384A (zh) 喹唑酮化合物作为抗癌药剂
CN1913884A (zh) 取代苯并唑及其作为raf激酶抑制剂的应用
JP4755991B2 (ja) Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
CN1305872C (zh) 喹唑啉类化合物的制备方法
KR100928602B1 (ko) 티로신 키나제 억제제로서 적합한 시클릭 디아릴 우레아
JP4828421B2 (ja) 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
CN1809563A (zh) 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
CN1910183A (zh) 四氢咔啉化合物作为抗癌药
CN1798749A (zh) 作为抗癌剂的杂芳基－稠合的嘧啶基化合物
CN1347416A (zh) 取代的3－氰基－[1.7],[1.5]和[1.8]－二氮杂萘酪氨酸激酶抑制剂
JP2007501212A (ja) Ｖｅｇｆ受容体型チロシンキナーゼの阻害薬としてのキナゾリン誘導体
CN1852714A (zh) 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN101039932A (zh) 作为激酶抑制剂的杂环取代的二芳基脲衍生物
HK1067945B (en) Substituted benzazoles and use thereof as raf kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: Novartis Vaccines & Diagnostic Inc.

Address before: American California

Applicant before: Chiron Corporation

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061220